News Room

A collection of press releases, audio content and media clips featuring INFORMS members and their research.

Study Reveals Hidden Economic Cost of Sponsored Content for Social Media Influencers
News Release

BALTIMORE, MD, February 25, 2025 – In an era in which influencer marketing dominates digital platforms, a groundbreaking study in the INFORMS journal Management Science unveils a surprising reality: sponsored content can harm an influencer’s reputation and reduce audience engagement.

Read More
OpenAI’s New Stargate Project and China’s DeepSeek: Goliath vs. David
Media Coverage

On Jan. 21, OpenAI launched the $500 billion Stargate Project with partners like Arm, Microsoft, NVIDIA, and Oracle. This initiative aimed to secure American AI leadership, create jobs, and boost the economy. Initially, this boosted the stock prices of these companies.

Read More
Resign or stay? Federal workers are on the clock — Here’s how decision-analysis tools can help
Media Coverage

Living in limbo: An estimated 2 million U. S. federal employees were thrust into a decision they did not seek to make. A deadline from the Trump Administration was halted last week, and is now in the hands of a judge. When a deadline is set those employees will have to make a high-stakes choice: Take a buyout and resign, or they can choose to stay in an uncertain job environment, including the possibility of being laid-off or having significant changes in work duties or leave with a buyout. This current reprieve gives these federal employees a little more time, but the fundamental question for each of them remains: What’s the right move for your career and future?

Read More

Resoundingly Human Podcast

An audio journey of how data and analytics save lives, save money and solve problems.

Media Contact

Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
asmith@informs.org
443-757-3578

INFORMS in the News

What are you looking for?

Type of Content
Topic
COVID-19 Vaccine Supply Chain Can Be Fixed

COVID-19 Vaccine Supply Chain Can Be Fixed

The Hill, January 11, 2021

The output from Operation Warp Speed is struggling to get its footing. The billions of dollars invested focused primarily on developing a safe and effective vaccine as quickly as possible. Equally needed was how to effectively traverse all the links in the supply chain, particularly the last mile, to transform those vaccines into vaccinations. As a result, millions of doses of vaccines sit on shelves while willing recipients anxiously await their turn to be immunized. What went wrong and what can be done today to make this right?  

There's Something to Gain in the Space Between Home and Work

There's Something to Gain in the Space Between Home and Work

Business Daily Media, January 11, 2021

For many of us, one of the upsides of 2020 was being freed from the grind of the daily commute. For the 40% of the workforce able to “telecommute”, COVID-19 social distancing measures saved us an average of about an hour a day – and much more for those of us living in the outer suburbs of cities. Studies show the morning commute is the least favourite part of the day, and the commute home the third-least favourite (working is the second-least favourite). Congestion, crowding and unpredictability increase stress and dissatisfaction. The longer it takes, and the more we have to do in the company of others, the more we dislike it.

When AI is Used to Set Prices, Can Inadvertent Collusion be a Result?

When AI is Used to Set Prices, Can Inadvertent Collusion be a Result?

News Release, January 12, 2021

CATONSVILLE, MD, January 12, 2021 – Machine learning and artificial intelligence (AI) are perfectly suited to help companies and marketers monitor and set prices based on real-time dynamic pricing. But new research has identified some possible unintended consequences of AI in this area.

New Year Starts with Challenges of COVID-19 Vaccine Rollout

New Year Starts with Challenges of COVID-19 Vaccine Rollout

Relias Media, January 1, 2021

Like certain celebrities, the “vaccine” does not need a first name or modifier. Data from both Pfizer and Moderna have shown their COVID-19 vaccines to be nearly 95% effective in preventing disease in people who received two doses, thus earning a green light from the Food and Drug Administration. Other vaccines in clinical trials also are showing promising results. Although vaccine doses have been distributed to all states, limited quantities will force states to prioritize those who should get the first doses.

As COVID-19 Vaccine Rolls Out, Leaders Need to Roll Up Sleeves

As COVID-19 Vaccine Rolls Out, Leaders Need to Roll Up Sleeves

Relias Media, January 1, 2021

The good news toward the end of 2020 was the emergency approval of two COVID-19 vaccines. Like certain celebrities, the “vaccine” did not need a first name or modifier. Everyone heard of the promising data coming out of Pfizer and Moderna, showing the vaccines to be about 95% effective against preventing COVID-19 in people who received two doses. Other vaccines also showed promising results, and the Food and Drug Administration has already given emergency use authorization (EUA) to the Pfizer and Moderna vaccines.

Subject Matter Experts in

Supply Chain

View list of experts

Subject Matter Experts in

Healthcare

View list of experts

INFORMS Magazines

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.

Access OR/MS Today Magazine

Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.

Access Analytics Magazine